Source comparison
CJC-1295 no DAC & Ipamorelin for Women: Peptide Stack Comparison
Research teams evaluating growth hormone secretagogues need clarity on how CJC-1295 no DAC & Ipamorelin for women compares to alternative peptide combinations. The table below outlines mechanism, female-specific considerations, typical research dosing, and bot
This comparison does not assign a generated winner or score.
- Research teams evaluating growth hormone secretagogues need clarity on how CJC-1295 no DAC & Ipamorelin for women compares to alternative peptide combinations. The table below outlines mechanism, female-specific considerations, typical research dosing, and bottom-line assessment for the most common GH peptide stacks.
- CJC-1295 no DAC + Ipamorelin
- GHRH analog + selective ghrelin agonist; synergistic GH pulse amplification
- Estrogen potentiates both pathways; cycle phase timing critical; no prolactin elevation
- 100–200mcg each peptide, dosed follicular phase or adjusted luteal
- Most selective and cycle-responsive option; minimal off-target effects; ideal for female models
- CJC-1295 with DAC + Ipamorelin
- Extended half-life GHRH (6–8 days) + ghrelin agonist
- DAC version blunts natural pulsatility; less adaptable to menstrual cycle phase changes
- 500–1000mcg CJC with DAC weekly + 200mcg Ipamorelin daily
- Less flexible for female physiology; single-dose convenience trades off cycle alignment capability
- GHRP-2 + Mod GRF 1-29
- Non-selective ghrelin agonist + GHRH analog
- GHRP-2 elevates cortisol and prolactin 20–40%; problematic in female models with baseline prolactin sensitivity
- 100–300mcg each peptide
- Inferior to Ipamorelin due to prolactin elevation; not recommended for female-specific research
- Ipamorelin monotherapy
- Selective ghrelin receptor agonist
- Effective but lacks synergistic GHRH amplification; 30–40% lower GH pulse amplitude vs combination
- 200–300mcg per dose
- Viable but suboptimal; combining with CJC-1295 no DAC increases efficacy 2–3×
- Sermorelin + GHRP-6
- GHRH analog + non-selective ghrelin agonist
- GHRP-6 increases appetite significantly; confounds metabolic studies in female models
- 200–300mcg each peptide
- Appetite stimulation makes body composition research difficult; CJC-1295 no DAC is superior GHRH choice
- For female-specific research, CJC-1295 no DAC & Ipamorelin remains the most versatile and hormonally compatible combination. The short half-life of CJC-1295 no DAC allows precise cycle-phase dosing, and Ipamorelin's selectivity avoids the cortisol and prolactin elevation that confounds interpretation in female models. Research-grade formulations like those available from Real Peptides undergo third-party purity testing and exact amino-acid sequencing verification. Critical quality controls that prevent the batch-to-batch variability that undermines reproducibility in peptide research.